VENTURE-AF

A study exploring two treatment strategies in patients with atrial fibrillation who undergo catheter ablation therapy (2013, ongoing)

Condition

Prevention of cardiovascular events in patients undergoing catheter ablation therapy for atrial fibrillation

Close this section

Objective

To assess the safety of uninterrupted rivaroxaban vs. usual care in patients undergoing catheter ablation therapy for non-valvular AF

Close this section

Trial design

Prospective, randomized, open-label, active-controlled phase III study
Active treatment: rivaroxaban 20 mg p.o. once daily
Control treatment: uninterrupted vitamin K antagonist (VKA), dose-adjusted to achieve a target international normalized ratio (INR) of 2.0–3.0

Close this section

Endpoints

Primary efficacy endpoint: incidence of post-procedure major bleeding during the first 30 ± 5 days after the catheter ablation procedure
Secondary outcome measures: event rate of myocardial infarction, ischemic stroke, non-central nervous system systemic embolism and vascular death

Close this section

Trial participants

~250 patients ≥18 years with a history of paroxysmal or persistent non-valvular AF who are scheduled to undergo their first elective catheter ablation procedure

Close this section

Reference

ClinicalTrials.gov (NCT01729871))

Close this section

Back To List

Recommend pageBack to top